B

Bavarian Nordic A/S
CSE:BAVA

Watchlist Manager
Bavarian Nordic A/S
CSE:BAVA
Watchlist
Price: 187.6 DKK -2.75% Market Closed
Market Cap: 14.8B DKK
Have any thoughts about
Bavarian Nordic A/S?
Write Note

Gross Margin
Bavarian Nordic A/S

56.9%
Current
46%
Average
63.9%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.9%
=
Gross Profit
3.5B
/
Revenue
6.1B

Gross Margin Across Competitors

Country DK
Market Cap 14.6B DKK
Gross Margin
57%
Country FR
Market Cap 6T USD
Gross Margin
0%
Country US
Market Cap 315.2B USD
Gross Margin
67%
Country US
Market Cap 141.9B USD
Gross Margin
60%
Country US
Market Cap 116.4B USD
Gross Margin
78%
Country US
Market Cap 104.5B USD
Gross Margin
86%
Country US
Market Cap 94.1B EUR
Gross Margin
76%
Country AU
Market Cap 135.7B AUD
Gross Margin
52%
Country US
Market Cap 78.7B USD
Gross Margin
87%
Country US
Market Cap 39.3B EUR
Gross Margin
75%
Country NL
Market Cap 36B EUR
Gross Margin
89%
No Stocks Found

Bavarian Nordic A/S
Glance View

Market Cap
14.6B DKK
Industry
Biotechnology

Bavarian Nordic A/S, established in 1994, is a Danish biotechnology powerhouse distinguishing itself in the development and production of vaccines for infectious diseases and immunotherapies for cancer. The company's journey from a promising start-up to a respected player in the global biotech landscape has been driven by its commitment to innovation and strategic partnerships. Its core operations revolve around a sophisticated platform technology capable of developing vaccines quickly and efficiently. This cutting-edge technology enables Bavarian Nordic to address urgent public health needs, such as growing threats from infectious diseases like smallpox, monkeypox, and Ebola. The company's facility in Kvistgaard is crucial to its operations, allowing it to seamlessly transition from research and development to large-scale production, ensuring a quick response to global health challenges. Revenue generation for Bavarian Nordic is predominantly through contracts and collaborations with governments, health organizations, and pharmaceutical companies. Over the years, the company has secured significant agreements, such as those with the U.S. government for the supply of its smallpox and monkeypox vaccines. These contracts provide a steady income stream, allowing the company to reinvest in its R&D efforts and expand its vaccine pipeline. Moreover, Bavarian Nordic’s strategic acquisitions, like their purchase of Rabipur/RabAvert and Encepur from GlaxoSmithKline, have expanded their portfolio and market presence, providing additional revenue channels. This approach not only sustains the company's growth but also aligns with its long-term vision of addressing unmet medical needs worldwide. By continually leveraging its proprietary technology and expanding its network of strategic collaborations, Bavarian Nordic is well-positioned to advance its mission in the global healthcare arena.

BAVA Intrinsic Value
509.91 DKK
Undervaluation 63%
Intrinsic Value
Price
B

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
56.9%
=
Gross Profit
3.5B
/
Revenue
6.1B
What is the Gross Margin of Bavarian Nordic A/S?

Based on Bavarian Nordic A/S's most recent financial statements, the company has Gross Margin of 56.9%.